Phase II study of nimotuzumab combination with paclitaxel and cisplatin as the first-line treatment in patients with local advanced or metastatic esophageal squamous cell cancer (ESCC): An interim analysis

被引：0
|
作者：
Zhang, Xiaodong
Lu, Ming
Gong, Jifang
Gao, Jing
Wang, Xicheng
Zhang, Xiaotian
Li, Jie
Li, Yan
Li, Jian
Zhou, Jun
Lu, Zhihao
Shen, Lin
机构：
[1] Peking Univ, Sch Oncol, Dept Gastrointestinal Oncol, Beijing 100871, Peoples R China
[2] Beijing Canc Hosp & Inst, Beijing, Peoples R China
[3] Peking Univ, Canc Hosp, Beijing 100871, Peoples R China
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2012年 / 30卷 / 15期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
e14604
引用
收藏
页数：1
相关论文
共 50 条
  • [41] Preliminary results of a phase II study of epirubicin and paclitaxel as first-line treatment in patients with metastatic breast cancer
    Luck, HJ
    Thomssen, C
    duBois, A
    Lisboa, BW
    Untch, M
    Kuhnle, H
    Janicke, F
    Meerpohl, HG
    Lindner, C
    Kcnecny, G
    Hecker, D
    Diergarten, K
    SEMINARS IN ONCOLOGY, 1997, 24 (01) : S13 - S16
  • [42] Phase II study of paclitaxel and epirubicin as first-line treatment in patients with metastatic nonsmall cell lung carcinoma
    Ceresoli, GL
    Dell'Oro, S
    Passoni, P
    Villa, E
    CANCER, 2000, 89 (01) : 89 - 96
  • [43] Fruquintinib plus camrelizumab combined with paclitaxel liposome and nedaplatin as first-line treatment for advanced esophageal squamous cell carcinoma (ESCC): A single-arm, phase II clinical trial
    Qiu, Tianzhu
    Mingjie, Lu
    Dong, Yuwen
    JOURNAL OF CLINICAL ONCOLOGY, 2025, 43 (4_SUPPL) : 445 - 445
  • [44] A Phase II Study of 5-Fluorouracil/Leucovorin in Combination with Paclitaxel and Oxaliplatin as First-Line Treatment for Patients with Advanced Gastric Cancer
    Lin, Rong-Bo
    Fan, Nan-Feng
    Guo, Zeng-Qing
    Wang, Xiao-Jie
    Liu, Jie
    Chen, Ling
    JOURNAL OF CHEMOTHERAPY, 2008, 20 (06) : 744 - 748
  • [45] A retrospective clinical study of comparing paclitaxel plus S-1 versus paclitaxel plus cisplatin as the first-line treatment for patients with advanced esophageal squamous cell carcinoma
    Wang, Hai-ying
    Yao, Zhi-hua
    Tang, Hong
    Zhao, Yan
    Jin, Shui-ling
    Zhou, Wen-ping
    Yao, Shu-na
    Yang, Shu-jun
    Liu, Yan-yan
    Luo, Su-xia
    ONCOTARGET, 2017, 8 (05) : 7540 - 7547
  • [46] First-line treatment with oxaliplatin and capecitabine in patients with advanced or metastatic oesophageal cancer: a phase II study
    E van Meerten
    F A L M Eskens
    E C van Gameren
    L Doorn
    A van der Gaast
    British Journal of Cancer, 2007, 96 : 1348 - 1352
  • [47] Nimotuzumab combined with chemotherapy plus immunotherapy as first-line treatment for advanced esophageal squamous cell carcinoma.
    Han, Quanli
    Wang, Qi
    Cui, Zhi
    Deng, Muhong
    Ma, Yue
    Pang, Fang
    JOURNAL OF CLINICAL ONCOLOGY, 2025, 43 (4_SUPPL) : 344 - 344
  • [48] First-line treatment with oxaliplatin and capecitabine in patients with advanced or metastatic oesophageal cancer: a phase II study
    van Meerten, E.
    Eskens, F. A. L. M.
    van Gameren, E. C.
    Doorn, L.
    van der Gaast, A.
    BRITISH JOURNAL OF CANCER, 2007, 96 (09) : 1348 - 1352
  • [49] Update results of paclitaxel and cisplatin in combination with anlotinib as first-line treatment for patients with advanced ESCC: A multicenter, single-arm, open-label phase II clinical trial
    Wang, J.
    Wu, T.
    Hong, Y-G.
    Luo, S-X.
    Li, N.
    Guo, Y-Z.
    Cheng, Y-F.
    ANNALS OF ONCOLOGY, 2021, 32 : S1058 - S1058
  • [50] Phase II study of MTX-HSA in combination with Cisplatin as first line treatment in patients with advanced or metastatic transitional cell carcinoma
    C. Bolling
    T. Graefe
    C. Lübbing
    F. Jankevicius
    S. Uktveris
    A. Cesas
    W.-H. Meyer-Moldenhauer
    H. Starkmann
    M. Weigel
    K. Burk
    A.-R. Hanauske
    Investigational New Drugs, 2006, 24 : 521 - 527
12345